title: Prognostic factors and outcome in relapsed multiple myeloma after nonmyeloablative allo-SCT: a single center experience.
abstract: For relapsed multiple myeloma (MM) patients, allo-SCT is a possible treatment option, but recent data obtained using a nonmyeloablative (NMA) conditioning regimen are scarce. We retrospectively collected data from 38 relapsed MM patients who received a NMA allo-SCT from October 2001 to January 2008. In total, 18 patients (48%) were transplanted using a matched unrelated donor. The median follow-up is 2.3 years. In 16 patients (42%) the response improved and eight patients (21%) were rapidly progressive within 6 months after allo-SCT. In total, 15 patients (39%) were in CR after allo-SCT. The median PFS was 1.4 years (range, 0.1-4.9), and having a CR after allo-SCT or having chronic GVHD resulted in longer PFS. Median OS was 3.1 years (range, 0.2-7.2) and again having a CR after allo-SCT or chronic GVHD was associated with a better OS. Six patients (16%) have died from treatment-related diseases. These results indicate that NMA allo-SCT is a treatment option in relapsed MM patients and that results may be improved by strategies that enhance the CR rate after allo-SCT.
authors.affiliation: Department of Hematology, UMC Utrecht, Utrecht, The Netherlands. m.c.minnema@umcutrecht.nl
authors.forename: M C
authors.initials: MC
authors.lastname: Minnema
authors.forename: S
authors.initials: S
authors.lastname: van Dorp
authors.forename: N W C J
authors.initials: NW
authors.lastname: van de Donk
authors.forename: F
authors.initials: F
authors.lastname: Schouten
authors.forename: M J
authors.initials: MJ
authors.lastname: Kersten
authors.forename: J L L M
authors.initials: JL
authors.lastname: Coenen
authors.forename: H
authors.initials: H
authors.lastname: Schouten
authors.forename: S
authors.initials: S
authors.lastname: Zweegman
authors.forename: R
authors.initials: R
authors.lastname: Schaafsma
authors.forename: H M
authors.initials: HM
authors.lastname: Lokhorst
mesh_terms: D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000494:pharmacology; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000401:mortality / Q000601:surgery*; D011379:Prognosis; D012008:Recurrence; D012189:Retrospective Studies; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
chemical_list: D000961:Antilymphocyte Serum